Brain cancer: Extended survival seen with vaccine
Plenty of readers engaged with a story published last month, one about a brain cancer vaccine succeeding at prolonging survival in a Phase 3 trial.
The readout of the study of Northwest Biotherapeutics’s DCVax-L vaccine indicated extended survival in patients with gliobastoma for many months, or in some cases, years.
Photo credit: GettyImages/asbe